⏳ Fetching live dividend data...
Home › Calculator › GEOVF Dividend Calculator 2026
Genovis AB (publ.) · OTC
Price: $7.34 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in GEOVF → $111.2K in 10 years · $1,983.45/month
Genovis AB (publ.), established in Lund, Sweden, in 1999, specializes in the creation and provision of advanced reagents essential for drug discovery and development. The company serves a diverse client base within the pharmaceutical and medical device sectors. Its core offerings predominantly feature a range of enzymes designed for precise modification and analysis of immunoglobulins (IgG). These include: FabALACTICA: A cysteine protease specifically tailored to digest human IgG1. FabRICATOR: An enzyme primarily targeting the hinge region of IgG for cleavage. FabRICATOR Z: An enzyme engineered for the digestion of mouse IgG2a and IgG3, facilitating the generation of homogenous F(ab')2 and Fc fragments. FabULOUS (SpeB): Another enzyme dedicated to cleaving IgG within its hinge region. GingisKHAN: A cysteine protease that performs a highly specific digestion of human IgG1, acting just above the hinge. GingisREX: A cysteine protease with the unique ability to specifically cleave peptide bonds C-terminally to arginine residues. For glycan manipulation, Genovis offers a comprehensive suite of endoglycosidases: IgGZERO (EndoS): An endoglycosidase derived from Streptococcus pyogenes that selectively hydrolyzes N-linked glycans found in the Fc-region of native IgG. IgGZERO LE: Also an S. pyogenes endoglycosidase, engineered to act on complex type N-glycans. deGlycIT: An immobilized form of the IgGZERO (EndoS) enzyme on agarose beads, used for the deglycosylation of Fc-glycans. GlycINATOR: An S. pyogenes endoglycosidase capable of hydrolyzing all glycoform structures. GlycINATOR (EndoS2): Another S. pyogenes endoglycosidase that specifically targets and hydrolyzes glycans at the Fc glycosylation site of IgG. Beyond these enzymatic solutions, the company also provides GlyCLICK, an innovative site-specific conjugation technology for IgG, which leverages enzymatic remodeling of Fc glycans combined with click chemistry. Additionally, they supply SialEXO, a sialidase product for the effective removal and subsequent analysis of sialic acids, along with enzymes specifically for O-glycans. Specialized antibody fragmentation services are also part of their portfolio, with all products available for purchase via their online store. Genovis's clientele encompasses pharmaceutical, biotech, contract research organizations (CROs), and contract manufacturing organizations (CMOs) across various global markets, including Sweden, Europe, North America, and Asia. The company maintains a significant strategic partnership with Waters Corporation.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GEOVF position with:
Real after-tax yield depends on where you live and how you hold GEOVF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 27.24% | 24.44% | $2,724 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 23.15% | 20.35% | $2,315 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 21.79% | 18.99% | $2,179 / yr |
| 🇬🇧 UK ISA | 0% | 27.24% | 24.44% | $2,724 / yr |
| 🇬🇧 UK Taxable | 8.75% | 24.86% | 22.06% | $2,486 / yr |
| 🇨🇦 TFSA | 0% | 27.24% | 24.44% | $2,724 / yr |
| 🇨🇦 CA Taxable | 25% | 20.43% | 17.63% | $2,043 / yr |
| 🇦🇺 Super (pension) | 15% | 23.15% | 20.35% | $2,315 / yr |
| 🇦🇺 AU Taxable | 30% | 19.07% | 16.27% | $1,907 / yr |
| 🇩🇪 DE Taxable | 26.375% | 20.06% | 17.26% | $2,006 / yr |
| 🇫🇷 FR Taxable | 30% | 19.07% | 16.27% | $1,907 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GEOVF pays quarterly — 4 times per year. Next ex-div: TBD.
How GEOVF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GEOVF sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GEOVF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Genovis AB (publ.) (GEOVF) is a healthcare stock currently trading at $7.34 with a dividend yield of 27.24%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →